Skip to main content
letter
. 2020 Mar 11;24:84. doi: 10.1186/s13054-020-2808-8

Table 1.

Overview of respondent’s input based on the survey

Responses
Total Europe U.S. Othera
Valid respondents 565 (100%) 208 (37%) 224 (40%) 133 (23%)
Role at ICU
 Critical care physician 509/565 (90%) 197/208 (95%) 186/224 (83%) 126/133 (95%)
 Infectious diseases physician 8/565 (1%) 4/208 (2%) 3/224 (1%) 1/133 (0.5%)
 Nurse 9/565 (2%) 1/208 (1%) 7/224 (3%) 1/133 (0.5%)
 Other 39/565 (7%) 6/208 (2%) 28/224 (13%) 5/133 (4%)
Number of ICU beds
 < 20 beds 176/554 (32%) 94/207 (46%) 27/222 (12%) 55/125 (44%)
 21–60 beds 226/554 (41%) 85/207 (41%) 89/222 (40%) 52/125 (42%)
 61–100 beds 68/554 (12%) 17/207 (8%) 43/222 (19%) 8/125 (6%)
 > 100 beds 84/554 (15%) 11/207 (5%) 63/222 (29%) 10/125 (8%)
Number of severe influenza cases per season
 < 10 cases 132/557 (23%) 56/206 (27%) 32/222 (14%) 44/129 (34%)
 11–30 cases 272/557 (49%) 118/206 (57%) 99/222 (45%) 55/129 (43%)
 31–50 cases 60/557 (11%) 18/206 (9%) 30/222 (14%) 12/129 (9%)
 >  50 cases 49/557 (9%) 10/206 (5%) 27/222 (12%) 12/129 (9%)
 I do not know 44/557 (8%) 4/206 (2%) 34/222 (15%) 6/129 (5%)
NAIs as standardized treatment
 Yes 416/556 (75%) 162/206 (79%) 165/222 (74%) 89/128 (70%)
 Yes, but only if influenza symptoms started ≤ 48–72 h before ICU admission 97/556 (17%) 34/206 (17%) 41/222 (19%) 22/128 (17%)
 No 27/556 (5%) 7/206 (3%) 3/222 (1%) 17/128 (13%)
 I do not know 16/556 (3%) 3/206 (1%) 13/222 (6%) 0
Obtaining lower respiratory samples
 Always 78/554 (14%) 52/205 (25%) 10/220 (5%) 16/129 (12%)
 Very often 139/554 (25%) 67/205 (33%) 43/220 (19%) 29/129 (22%)
 Sometimes 187/554 (34%) 50/205 (24%) 97/220 (44%) 40/129 (31%)
 Rarely 129/554 (23%) 31/205 (15%) 65/220 (29%) 33/129 (26%)
 Never 16/554 (3%) 5/205 (3%) 1/220 (1%) 10/129 (8%)
 N/A—have not treated patients 5/554 (1%) 0 4/220 (2%) 1/129 (1%)
Galactomannan testing in BAL
 Always 52/551 (9%) 38/204 (19%) 5/220 (2%) 9/127 (7%)
 Very often 65/551 (12%) 38/204 (19%) 14/220 (6%) 13/127 (10%)
 Sometimes 107/551 (19%) 37/204 (18%) 46/220 (21%) 24/127 (19%)
 Rarely 163/551 (30%) 43/204 (21%) 83/220 (38%) 37/127 (29%)
 Never 143/551 (26%) 44/204 (21%) 61/220 (28%) 38/127 (30%)
 N/A—have not treated patients 21/551 (4%) 4/204 (2%) 11/220 (5%) 6/127 (5%)
Galactomannan testing in serum
 Always 39/554 (7%) 28/205 (14%) 5/220 (2%) 6/129 (5%)
 Very often 60/554 (11%) 36/205 (18%) 11/220 (5%) 13/129 (10%)
 Sometimes 115/554 (21%) 42/205 (20%) 46/220 (21%) 27/129 (21%)
 Rarely 175/554 (31%) 47/205 (23%) 94/220 (43%) 34/129 (26%)
 Never 142/554 (26%) 48/205 (23%) 51/220 (23%) 43/129 (33%)
 N/A—have not treated patients 23/554 (4%) 4/205 (2%) 13/220 (6%) 6/129 (5%)
Number of IAPA in influenza patients in the past 5 years
 No 347/553 (63%) 85/204 (41%) 183/220 (83%) 79/129 (61%)
 Yes, 1 patient 77/553 (14%) 34/204 (17%) 21/220 (9%) 22/129 (17%)
 Yes, 2–5 patients 99/553 (18%) 61/204 (30%) 15/220 (7%) 23/129 (18%)
 Yes, > 5 patients 30/553 (5%) 24/204 (12%) 1/220 (1%) 5/129 (4%)

Descriptive statistics were used to analyze the differences in proportions of responses between Europe, the US, and other countries. Fisher’s exact or χ2 test was used to calculate the p values. Correction for multiple comparisons was applied. The Spearman rank-order correlation coefficient was used to determine univariate correlations between parameters. A p value of < 0.05 was considered statistically significant. Results were analyzed using SPSS (IBM SPSS Statistics version 26). ICU intensive care unit, N/A not applicable, BAL bronchoalveolar lavage, IAPA influenza-associated pulmonary aspergillosis

aOther countries + unknown